Replies to post #124225 on Biotech Values

[jq1234]

avonex didn't look very good either

Avonex doesn't have to look good. At least it achieved stat significance both before and after adjustment. It looked much better than Laquinimod in BRAVO.

Laquinimod reduced relapses by 17.6 percent versus placebo, though the result wasn’t statistically significant, Teva executives said on the call. After accounting for the MRI differences, laquinimod showed a statistically significant 21 percent reduction in relapses. Biogen’s Avonex cut relapses by 29 percent after the adjustment and by 26 percent prior to it, executives said.

[genisi]

Avonex, despite being the best selling interferon beta, is considered the less efficient drug (its short term efficacy as shown in Rebif's EVIDENCE trial) among ABRC therapies.